Winton Group’s Emergent Biosolutions EBS Stock Holding History

Winton Group’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$383K	Buy	45,744 +32,415	+243%	+$271K	0.01%	799
2026 Q1	$111K	Sell	13,329 -15,768	-54%	-$163K	﹤0.01%	1034
2025 Q4	$360K	Buy	29,097 +8,681	+43%	+$93K	0.01%	705
2025 Q3	$180K	Buy	+20,416	New	+$159K	0.01%	679
2022 Q1	–	Sell	-39,524	Closed	-$1.72M	–	1012
2021 Q4	$1.72M	Buy	+39,524	New	+$1.79M	0.1%	273
2018 Q3	–	Sell	-5,557	Closed	-$281K	–	1040
2018 Q2	$281K	Sell	5,557 -204	-4%	-$10.6K	0.01%	856
2018 Q1	$303K	Buy	+5,761	New	+$287K	0.01%	975

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Winton Group's EBS Position: Q2 2026 in Review

Winton Group increased its Emergent Biosolutions (EBS) stake by 243% in Q2 2026, buying an estimated $271K and bringing the position to 45,744 shares worth $383K. The position accounts for 0.01% of the portfolio, ranked #799.

Winton Group first reported a position in EBS in Q1 2018 and has held it in 7 quarters since. The position peaked at $1.72M in Q4 2021. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

Winton Group held 45,744 shares of Emergent Biosolutions worth $383K as of Q2 2026.
Winton Group bought 32,415 Emergent Biosolutions shares in Q2 2026, an estimated $271K.
Emergent Biosolutions made up 0.01% of Winton Group's portfolio in Q2 2026, its #799 holding.
Winton Group first reported a position in Emergent Biosolutions in Q1 2018 and has held it in 7 quarters since.
Winton Group's Emergent Biosolutions position peaked at $1.72M in Q4 2021.
194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.